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INTRODUCTION
Histone acetylation is the most thoroughly studied and appreciated post-translational modifi cation mechanism (Grunstein, 1997) . Generally, transcriptionally activeeuchromatin domains tend to be relatively hyperacetylated whereas transcriptionally repressed heterochromatin domains arehypoacetylated Gui et al., 2004) . The acetylation status of histones is regulated by the opposing action of two classes of enzymes, histone acetyl transferases (HATs) and histone deacetylases (HDACs) (Struhl, 1998; Kouzarides, 2000) . Acetylation of the histone tails enhance the accessibility of transcription factors, transcriptional regulatory complexes, and RNA polymerases to promoter regions of DNA (Reynisdóttir et al., 1995; Richon et al., 2000; Roth et al., 2001; Rosato et al., 2001) . This explains the role of HATs as transcriptional coactivators, and DNA binding proteins including PCAF (p300/cyclic AMP-response-element binding protein-associated factor) and members of the p300/ CBP family of transcriptional coactivators can recruit them to
In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes associated with cancer, and several classes of HDAC inhibitors have been found to have potent and specifi c anticancer activities in preclinical studies. But their precise mechanism of action has not been elucidated. In this study, a novel synthetic inhibitor of HDAC, 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide [IN-2001] was examined for its antitumor activity and the underlying molecular mechanisms of any such activity on human breast cancer cell lines. IN-2001 effectively inhibited cellular HDAC activity (IC 50 = 0.585 nM) inMDA-MB-231 human breast cancer cells. IN-2001 caused a signifi cant dose-dependent inhibition of cell proliferation in estrogen receptor (ER) negative MDA-MB-231human breast cancer cells. Cell cycle analysis revealed that the growth inhibitory effects of IN-2001 might be attributed to cell cycle arrest at G 0 /G 1 and/or G 2 /Mphase and subsequent apoptosis in human breast cancer cells. These events are accompanied by modulating several cell cycle and apoptosis regulatory genes such as CDK inhibitors p21 WAF1 and p27 KIP1 cyclin D1, and other tumor suppressor genes such as cyclin D2. Collectively, IN-2001 inhibited cell proliferation and induced apoptosis in human breast cancer cells and these fi ndings may provide new therapeutic approaches, combination of antiestrogen together with a HDAC inhibitor, in the hormonal therapy-resistant ER-negative breast cancers. In summary, our data suggest that this histone deacetylase inhibitor, IN-2001 , is a novel promising therapeutic agent with potent antitumor effects against human breast cancers. κB (NF-κB) and proteins with diverse biological functions such as α-tubulin, Ku70, and heat-shock protein 90 (Hsp90) (Blobel, 2000) . While histones still represent primary targets for the physiological function of HDACs, the antitumor effects of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of non-histone targets. HDACinhibitors can affect tumor cell growth andsurvival through multiple biological effects. HDACinhibitors induce cellcycle arrest and apoptosis, and have anti-angiogenic andimmunomodulatory effects by modulating the acetylation of a series of non-histone proteins. HDACinhibitors have been found to inducecell growth arrest, differentiation, and/orapoptosis, and exhibit potent antimetastatic, antiangiogenic, and immuno-modulatory properties in a variety of transformed cells in vitro and in vivo that cancontribute to the inhibition of tumour development andprogression (Marks et al., 2000; Johnstone, 2002; Johnstone and Licht, 2003) . The treatment of normal and tumor cells with HDAC inhibitors causes a similar accumulation of acetylated histones H4, H3, H2A, H2B Vigushin et al., 2001; Vigushin and Coombes, 2002) . Nevertheless, tumor cells appear to be much more sensitive to growth arrest, differentiation, and apoptotic effects of these agents than normal cells (Qui et al.,1999; Butler et al., 2000a Butler et al., , 2000b Butler et al., , 2001 Johnstone, 2002) .
In this study, we tried to evaluate the anti-tumor effects of various HDAC inhibitors on MDA-MB-231 human breast cancer. Moreover, the underlying chemotherapeutic mechanisms of them were explored also. To examine the anti-tumor effect of HDAC inhibitors, we examined the effect of HDAC inhibitors on the cell proliferation, cell cycle distribution, and apoptosis in MDA-MB-231 human breast cancer cells. To fi nd out the mechanism of anti-tumor activity of HDAC inhibitors, we examined the effect of IN-2001 on the expression of cell cycle regulatory protein and apoptosis-related proteins.
MATERIALS AND METHODS

Chemicals
HDAC inhibitors, such as Trichostatin A, IN2001, SAHA, and LAQ were generously provided from Dr. D. K. Kim (EwhaWomansUniversity, Seoul, South Korea). HC toxin was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Sodium pyrubate, penicillin-streptomycin, fetal bovine serum (FBS), trypsin-EDTA, minimum essential medium (MEM), and RPMI were acquired from GibcoBRL (Rockvulle, MD, USA). Antibodies were from Santa Crutz Biotechnology Inc. (Santa Crutz, CA, USA).
Cell lines and cell culture conditions
MDA-MB-231 cells were obtained from Korean Cell Line Bank (KCLB, Seoul, South Korea). MDA-MB-231 cells were maintained in RPMI1640 medium, supplemented with fetal bovine serum and penicillin-streptomycin. Cells were routinely maintained at 37 o C and in 5% CO 2 .
Cell proliferation assay
Cells were plated in 96 well plates and were treated with chemicals. Cells were treated with cold 10% trichloroacetic acid (TCA) and TCA-fi xed cells were stained for 30 min with 0.4% (w/v) sulforhodamineB (SRB) dissolved in 1% acetic acid. Bound dye was solubilized with 10 mMTris base (pH 10.5) and optical dencity was read usingELISA reader (BioRad, Hercules, CA, USA) at 570 nm.
Flow Activated Cell Sorter (FACS) Analysis
Chemicals treated cells were detached using trypsin-EDTA and fi xed with 70% ethanol. After centrifugation, the cells were treated with RNase A (10 μg/ml) and stained with propidium iodide (2 μg/ml). The DNA content per cell was evaluated in a FACScalibur (Becton Dickinson,San Diego, CA, USA).
RT-PCR analysis
Total RNA was extracted using Trizol reagent (Invitrogen Co., Carlsbad, CA, USA) from cells were exposed to chemicals for 24 hr. Reverse transcription was carried out on total RNA in a mixture containing random prime, dNTPs, DTT, RT buffer (5X), M-MLV reverse transcriptase, RNase in at 37 o C for 1 hr. cDNA was stored at -20 o C or cDNA was subjected to PCR amplifi cation with special primer (GAPDH; 5'AC ATCgCTCAgACACCATgg3'; 5'gTAgTTgAggTCAAT g AAggg3': p21; 5'gAACTTCgACTTTgTCACCgAg3'; 5'Cg TTTTCgACCCTgAg AgTCTC3': Cyclin D1; 5'AgCCATggAACACCAgCTC3'; 5'gCACCTCCAgCATCCAggT3': Cyclin D2;5' T A CTTCAAgTgCgTgCAgAAggAC3'; 5' TCCCACACTTCCAgTTgCgATCAT3') in reaction containing dNTP and Taqpolymerase. DNA was denatured at 95 o C extended at 72 o C and PCR products were analyzed on 2% agarose gels.
Western blot analysis
After the incubation with chemicals for 24 hr, cells were homogenized in a lysis buffer (Pro-prep protein extraction solution, INtRON; 20 mMTris, 160 mMNaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM PMSF, 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mM sodium orthovanadate, pepstatin, leupeptin, and aprotinin) on ice and cell lysates were centrifuged at 14,000 g for 5 min at 4°C, divided into aliquots and stored at -80°C. Protein was separated by electrophoresis on 10-15% SDS-acrylamide gels and then electrophoretically transferred to polyvinylidenedifl uoride (PVDF) transfer membrane (Hybond-P; Amersham). Membranes were blocked with 3% dry milk in PBST www.biomolther.org (PBS with 0.1% Tween) over night at 4°C and incubated with specifi c fi rst antibodies and second antibodies conjugated to horse radish peroxidase. Membranes were washed and air dried for ECL detection (ECL Plus; Amersham).
RESULTS
IN-2001 causes dose-dependent growth inhibition
In recent years, an increasing number of structurally diverse HDAC inhibitors have been identifi ed as an exciting new class of potential anti-cancer agents. In this study, we evaluated the anti-tumor effects of various kinds of HDAC inhibitors ( Table 1 . These data indicated that the anti-proliferative effects of HDAC inhibitors were cell type specifi c and ER positive breast cancer cells seemed to be more susceptible to HDAC inhibitors than ER negative breast cancer cells.
IN-2001 time-dependent growth inhibition
In the next experiment, we carried out time-course experiment with 1 μM IN-2001. As shown in 
IN-2001 increases p21
WAF1 and p27 KIP1 expression
In the previous study, we found that HDAC inhibitors induced cell cycle arrest. In relation to cell cycle arrest, we examined the effects of HDAC inhibitorson the cell cycle regulatory proteins, such as cyclins and cyclin dependent kinase (Fig. 6) . IN-2001 , and SAHA treatment showed 1.9-fold, and 1.4-fold increase in p21 WAF1 protein level, respectively. In addition, p27 KIP1 protein level was also increased to 2.6-fold, and 1.5-fold with IN2001, and SAHA, respectively. These results suggested that the HDAC inhibitor-induced up-regulation of cdk inhibitor may lead to cell cycle arrest, ultimately resulting in growth inhibition.
IN-2001 decreases cyclin D1 expression and increases cyclin D2 expression
As well as cdk inhibitors, one of the important cell cycle regulatoryproteins is cyclin. In this study, we examined the effect of IN-2001 on the expressions of D-type cyclin (cyclin D1 and cyclin D2). MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM IN-2001 for 24 hr and then examined for the expression of cyclin D1 and cyclin D2 by RT-PCR analysis. In MDA-MB-231 cells, TSA, HC toxin, and LAQ signifi cantly down-regulated cyclin D1 mRNA level but did not change cyclin D2 mRNA level. Cyclin D2 mRNA level was up-regulated by IN2001 and SAHA to 1.6-fold and 1.8-fold, respectively (Fig. 7) .
HDAC inhibitor decreases thymidylate synthase expression
Thymidylate synthase (TS) is an essential enzyme for DNA replication and repair because it provides the sole intracellular source of dTMP. Thus, it has been a major target of chemotherapeutic agents, such as fl uoropyrimidines (i.e. 5-FU) and antifolates (i.e. TDX, ZD931, and MTA). Therefore, we examined the effect of HDAC inhibitor on the TS gene expression. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr and then TS mRNA level was determined using RT-PCR technique. As shown in Fig.  8 , TSA, HC toxin, IN2001, and LAQ treatment decreased TS mRNA level to 24%, 22%, 80%, and 33% of control level, respectively in MDA-MB-231 cells. But SAHA did not show sig- Fig. 5 . Effect of HDAC inhibitor on the expression of cdk inhibitor. MDA-MB-231 cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specific primers. GAPDH served as loading control. For quantifi cation, the band intensity of p21WAF1 was normalized to that of GAPDH and data was expressed as fold induction compared to control group. www.biomolther.org nifi cant changes in TS expression, instead slightly increased TS expression.
HDAC inhibitor induces dose-dependent apoptosis
To determine whether anti-proliferative effect of HDAC inhibitor is related with induction of apoptosis, we examined the effect of HDAC inhibitor on the apoptosis. Moreover, we tried to elucidate the underlying mechanism of apoptosis induced by HDAC inhibitors. MDA-MB-231 cells treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for various time period (12 hr, 24 hr, or 48 hr). And then cell were stained with fl uorescent PI dye and then subjected to FACS analysis to measure the sub-G 1 populations, which represent apoptotic cells with less than 2N DNA content. In MDA-MB-231 cells, 1 μMHDAC inhibitors did not show signifi cant sub-G 1 peak when cells were exposed for 12 hr. As the exposure time increased, apoptotic cells were detected. TSA, HC toxin, and LAQ treatement for 24 hr showed 7%, 7.6%, and 8% of sub-G 1 peak, respectively, whereas untreated control cells showed 2.1% of sub-G 1 peak. When cells were exposed to HDAC inhibitors for 48 hr, HDAC inhibitors except SAHA increased apoptotic peak ranging from 7.6% to12.9% compared to the control value of 2.6%. However, 1 μM SAHA did not show apparent apoptotic sub-G 1 peak (Fig. 9) .
DISCUSSION
In cancer, some genes are transcriptionally silenced by the inappropriated recruitment of HDACs, e.g., tumor suppressor genes (Glaser et al., 2003) . Known repressors are multiproteins that contain DNA binding proteins (e.g., NcoR, SMRT, MEF, MeCP2, and sin3A) that commonly use HDACs to repress transcription and block the function of the tumor suppressor gene. The arche-typical gene silenced in this manner in human cancer is the cyclin-dependent kinase inhibitor p21
WAF1
. Epigenetic reactivation of p21 WAF1 by HDAC inhibitors has been reported in cancer cell lines (Archer et al., 1998) , and the restoration of p21 WAF1 gene expression by HDAC inhibitors Protein extracts were prepared and 50 μg of protein extracts were separated by 12% SDS-PAGE. Blots were probed with the corresponding antibodies. Actin served as the loading control. For quantifi cation, the band intensity of p21 WAF1 and p27 KIP1 was normalized to that of Actin and data was expressed as fold induction compared to control group. is associated with enrichment of hyperacetylated histones at the p21 WAF1 promoter (Gui et al., 2004) . Demethylatingagents such as 5-aza-2'-deoxycytidine are particularly interesting owing to the interaction of DNA methylation with histone deacetylation in gene silencing of tumor suppressor genes. Combinations of 5-aza-2'-deoxycytidine with HDAC inhibitors, TSA or depsipeptide, were shown to reactivate silenced tumor suppressor genes including MLH1, TIMP3, CDKN2B, CDKN2A, ARHI, gelsolin, and maspin, synergistically increasing the level of tumor cell apoptosis (Drummond et al., 2005) . Marks et al. (2001) have proposed a mechanism of action of HDAC inhibitors that induce tumor growth arrest, differentiation, and/ or apoptosis. With inhibition of HDAC, histones are acetylated, and the DNA that is tightly wrapped around a highly charged deacetylated histone core relaxes. Inhibition of HDAC activity generates acetylation of histones in nucleosomes, resulting in a more open chromatin structure. The relaxed chromatin structure allows expression of specifi c set of programmed genes, which, in turn, leads to cell growth arrest, differentiation, and/or apoptotic cell death and, as a consequence, inhibition of tumor growth. HDAC inhibitors may achieve their antitumor effects through reactivation of dormant tumor suppressor genes (Finnin et al., 2001; Finzer et al., 2001; Furumai et al., 2001; Fournel et al., 2002; Villar-Garea et al., 2004) . In addition to stand alone-therapeutics for chemotherapy, HDAC inhibitors seem to be suitable for combination therapy as "sensitizer drugs", enhancing the antitumor effects of specifi c chemotherapeutics. In fact, a proportion of the clinical trials using HDAC inhibitors involve a combination of an established antitumor compound together with a HDAC inhibitor (Cress and Seto, 2000; Chan et al., 2001; de Ruijter et al., 2003; Villar-Garea et al.,2004) . The drug combinations may have 2 advantages: fi rst, the dose of each substance necessary for cell growth inhibition or apoptosis is usually much lower than if used separately, reducing side effects and toxicity, and second, resistance to certain chemicals can be overcome in some cases by combining drugs. For instance, cell death after treatment with etoposide, comptothecin, and other substances that cross-link DNA and Topo II enzymes increases if the cell lines are pretreated with either TSA and SAHA, probably because the chromatin changes caused by the hydroxamic acids facilitate cross-linker access to the target. Combinations of nuclear receptor ligands, such as all trans retinoic acid (ATRA), or vitamin D analaogs, such as 1,25-dihydroxyvitamin D, with HDAC inhibitors have been shown to increase differentiation and apoptosis in cancer cells and also inhibit tumor growth in vivo (Banwell et al., 2003; Bulavin et al., 2004; Drummond et al., 2005) . Fig. 8 . Effect of HDAC inhibitor on the thymidylate synthase expression. MDA-MB-231cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specific primers for thymidylate synthase. GAPDH served as the loading control. For quantifi cation, the band intensity of TS was normalized to that of GAPDH and data was expressed as fold induction compared to control group.*Signifi cantly different from control (p<0.05). 
